Promising drug combo takes on tough childhood bone cancer
NCT ID NCT05830084
First seen Jan 08, 2026 · Last updated Jun 17, 2026 · Updated 22 times
Summary
This early-phase study tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The trial enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The goal is to find a safe dose and see if the combination can improve outcomes for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Bordeaux
Bordeaux, France
-
Centre Oscar Lambret
Lille, France
-
Gustave Roussy
Villejuif, Île-de-France Region, 94805, France
-
Institut Curie
Paris, France
-
Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Monash Children's Hospital
Clayton, Australia
-
Perth Children's Hospital
Perth, WA6009, Australia
-
Princess Máxima Center
Utrecht, 113, Netherlands
-
Queensland Children's Hospital
Brisbane, Australia
-
Rigshospitalet
Copenhagen, DK-2100, Denmark
-
Royal Children's Hospital
Parkville, Australia
-
Vall d'Hebron University Hospital
Barcelona, 119-12, Spain
-
centre Léon Bérard
Lyon, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.